Drug Pipeline

sparsentan Clinical Trials

Data updated daily from ClinicalTrials.gov — last refresh 2026-06-12
6
Active Studies
3
Recruiting
1
Phase 3
4
Top Sponsors
Active Studies by Phase
Phase 4
1
Phase 3
1
Phase 2
2
Phase 1
1
Not specified
1
Active Trials
NCT IDTitleConditionStatus
Phase 4
NCT07219121 Sparsentan in Posttransplant Immunoglobulin A Nephropathy or Focal Segmental… Proteinuria Recruiting
Phase 3
NCT03762850 A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA… Immunoglobulin A Nephropathy Active, Not Recruiting
Phase 2
NCT05003986 Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases Focal Segmental Glomerulosclerosis Recruiting
NCT04663204 A Study of the Safety and Activity of Sparsentan for the Treatment of Patients With… Immunoglobulin A Nephropathy Recruiting
Phase 1
NCT07224776 Sparsentan for the Treatment of VEGF Signaling Pathway Inhibitor-Associated Proteinuria Proteinuric Renal Disease Not Yet Recruiting
Not specified
NCT07555301 Clinical Experience With Sparsentan in Switzerland in IgA Nephropathy IgA Nephropathy (IgAN) Not Yet Recruiting
Sponsors Running sparsentan Trials
Travere Therapeutics, Inc. (3) University of Leicester (1) Brigham and Women's Hospital (1) Waid City Hospital, Zurich (1)
Disease Areas
Chronic Kidney Disease (2)
Get alerts when sparsentan trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free